{
    "nct_id": "NCT04130542",
    "official_title": "An Open Label, First in Human (FIH), Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy",
    "inclusion_criteria": "* Males or females aged ≥ 18 years.\n* Ability to understand and willingness to sign a written informed consent document.\n* Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy.\n* Estimated life expectancy, in the judgment of the Investigator, of at least 90 days.\n* Adequate bone marrow, liver, and renal functions.\n* Men and women of childbearing potential must agree to take highly effective contraceptive methods.\n* Patients should recover from all reversible AEs of previous anticancer therapies to baseline.\n* Patients infected with the HIV virus will be eligible if the disease is under control of effective therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receipt of systemic anticancer therapy including investigational agents or devices within 5 half-lives of the first dose of study treatment.\n* Previous radiotherapy within 14 days of the first dose of study treatment.\n* Known active CNS metastasis and/or carcinomatous meningitis.\n* Has received a live-virus vaccine within 30 days.\n* Has had a Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody.\n* Abnormality of QT interval or syndrome.\n* Patients with history of Grade ≥ 3 immune-related AEs (irAEs) or irAE.\n* Patients who are receiving an immunologically-based treatment for any reason.\n* Treatment with systemic immune-stimulatory agents within 4 weeks prior to the first dose of study drug.\n* Active or chronic autoimmune disease that has required systemic treatment in the past 2 years or who are receiving systemic therapy for an autoimmune or inflammatory disease.\n* Has a clinically significant cardiac condition, including unstable angina, acute myocardial infarction within 6 months.\n* Has an active infection requiring intravenous (i.v.) anti-infectives within 14 days before the first dose of study treatment.\n* Current evidence or history of interstitial lung disease or active, noninfectious pneumonitis requiring treatment such as oral or intravenous glucocorticoids to assist with management.\n* Female patients who are pregnant or breastfeeding.\n* Any evidence of severe or uncontrolled systemic disease.\n* Any other disease or clinically significant abnormality in laboratory parameters.\n* Has previously had a stem cell or bone marrow or solid organ transplant.",
    "miscellaneous_criteria": ""
}